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ABSTRACT
Interactions between proteins and small molecules
are an integral part of biological processes in liv-
ing organisms. Information on these interactions is
dispersed over many databases, texts and predic-
tion methods, which makes it difficult to get a com-
prehensive overview of the available evidence. To
address this, we have developed STITCH (‘Search
Tool for Interacting Chemicals’) that integrates these
disparate data sources for 430 000 chemicals into
a single, easy-to-use resource. In addition to the in-
creased scope of the database, we have implemented
a new network view that gives the user the ability to
view binding affinities of chemicals in the interac-
tion network. This enables the user to get a quick
overview of the potential effects of the chemical on
its interaction partners. For each organism, STITCH
provides a global network; however, not all proteins
have the same pattern of spatial expression. There-
fore, only a certain subset of interactions can occur
simultaneously. In the new, fifth release of STITCH,
we have implemented functionality to filter out the
proteins and chemicals not associated with a given
tissue. The STITCH database can be downloaded
in full, accessed programmatically via an extensive
API, or searched via a redesigned web interface at
http://stitch.embl.de.
INTRODUCTION
The role of small molecules in biological systems can be
understood only in the relation to the function of the tar-
geted biomolecules, which, in turn, is largely defined by their
interaction partners (1–3). The role of the interaction net-
work is even more prominent in the area of the drug devel-
opment, since diseases are often a consequence of multiple
changes in the same pathway or protein complex (4,5). Tak-
ing into account the neighborhood of the targeted proteins
and the topology of the network itself can lead to a bet-
ter understanding of a drug’s cellular impact (6,7). Further-
more, as only a subset of all proteins are viable drug targets
(8), most therapeutics target proteins in the network vicin-
ity from more prospective, but undruggable, proteins (7).
Several databases provide proteome-wide protein–chemical
interactions (9–11) and several other (12–14) put protein–
chemical interactions in the context of protein–protein in-
teraction networks, which is essential for effective in silico
drug discovery.
A drug’s impact on the organism and its efficacy depend
on its engagement with the targeted proteins and the ex-
tent to which it disrupts the protein–protein and protein–
chemical interaction network (7,15). This is related to the
concentration of the drug, the strength with which it modu-
lates the activity of the target, and the distribution of target
proteins among different tissues (16). To enable the users to
rationally select possible drug targets, we have added two
new features to STITCH: a new mode that allows users to
show known binding affinities between proteins and chem-
icals, and the ability to filter the network to show only pro-
teins related to a selected tissue.
STITCH, in its fifth release, shares protein space with
STRING v10 (17) and now encompasses more than
9 600 000 proteins from 2031 eukaryotic and prokary-
otic genomes. Also, its chemical space grew by a quarter
compared to the previous version (18), from 340 000 to
430 000 compounds (not including different stereoisomers).
STITCH is available through new redesigned web interface
at http://stitch.embl.de and via an extensive API that al-
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lows programmatic access, including the ability to disam-
biguate queries, modify all network parameters and gen-
erate images. In order to enable large-scale analysis, which
may not be feasible through web-interface or API, the pre-
computed network and the supplementary information are
freely available for download.
SOURCES OF INTERACTIONS
Although there is a plethora of data available from which
protein–chemical networks could be derived, their dis-
persed nature, different precision, name-space and focus
make it cumbersome to assemble a full picture of all avail-
able knowledge. The STITCH pipeline aggregates high-
throughput experiments data, manually curated datasets
and the results of several prediction methods into a single
global network of protein–protein and protein–chemical in-
teractions. This does not expose the user to the heterogene-
ity of the underlying data, yet, at the same time, keeps all
the primary evidence of the interaction readily accessible.
A large part of the known interactions comes from man-
ually curated datasets such as DrugBank (19), GPCR-
ligand database (GLIDA) (20), Matador (21), the Thera-
peutic Targets Database (TTD) (22) and the Comparative
Toxicogenomics Database (CTD) (23), and several path-
way databases including the Kyoto Encyclopedia of Genes
and Genomes (KEGG) (12), NCI/Nature Pathway Inter-
action Database (24), Reactome (25) and BioCyc (26). As
there can be overlap between different manually curated
datasets, we do not consider multiple reports of identi-
cal interactions as being independent from each other. In-
stead, we count redundant interactions only once and do
not increase the confidence level. Other large sources of
protein–chemical links are the datasets of experimentally
validated interactions, which include ChEMBL (27), PDSP
Ki Database (28), Protein Data Bank (PDB) (29) and two
high-throughput kinase–ligand interactions studies (30,31).
Also in this case, interactions may be reported in different
databases and with different binding affinities. To compute
the final confidence score, we only take the strongest re-
ported affinity into account.
The sources of verified protein–chemical interactions are
complemented by automated text mining and a structure-
based prediction method (18). The text-mining pipeline in-
clude co-occurrence text-mining and natural language pro-
cessing of all MEDLINE abstracts as well as available
PubMed Central open-access full-text articles (32). The
newest addition to the text-mining sources are NIH Re-
PORTER grant abstracts (https://projectreporter.nih.gov/).
Considering co-occurring terms, adding the RePORTER
data increased the number of high-confidence interactions
between human proteins and chemicals from 2740 to 4740.
Extensive benchmarking of each data source allows us to
provide unified confidence score for every interaction while
taking into account the sources’ predicted precision.
DISPLAY OF BINDING AFFINITIES IN THE NETWORK
VIEW
Small molecules that activate or inhibit proteins such as en-
zymes or receptors are among the most studied classes of
exogenous small molecules. In order to assess the effect and
confidence of protein–ligand binding, as well as variabil-
ity in the affinity of known ligands, it is essential to know
the binding affinity between the compound and its target.
Usually, this binding affinity is quantified as the inhibition
constant Ki. In some cases, Ki values are not available, but
other values such as the IC50 or EC50 (half of the maxi-
mal inhibitory concentration) can serve as an approxima-
tion. Ki values of drugs vary greatly, from nanomolar in-
hibition constants to relatively high values, such as 52 M
between aspirin and cyclooxygenase 2 (27). Therefore, for
any given drug, it is not so much the absolute value of the
Ki, but rather the relative binding affinities that determine
the impact on the interaction network.
In previous versions of STITCH, Ki values from primary
sources (27,28) were accessible to the user through the web-
interface. In the new release of STITCH, the user can now
choose to switch the network view to show the binding
affinities of all protein–chemical interactions for which this
value is known (Figure 1). This new network view is similar
to the STITCH’s confidence view: the thickness of the edge
between nodes scales with the Ki value. If a Ki is not avail-
able, EC50 or IC50 will be used to determine the depicted
strength of the interaction. If there are multiple measure-
ments available, the lowest value (i.e. highest reported affin-
ity) will be used to determine the thickness of the edge.
DATA AND FILTERING FOR TISSUE SPECIFICITY
The protein–chemical network in STITCH is global and
as such considers interactions anywhere in an organism.
However, in multicellular organisms such as humans, not
all proteins are present in every tissue. STITCH 5 addresses
this through a new feature that allows users to filter a
human interaction network so that only the proteins be-
lieved to be present in a specified tissue are shown (Fig-
ure 2). To provide this feature, STITCH now integrates
tissue-specific protein expression patterns from two data
sources. First, the TISSUES resource (33), which combines
evidence from UniProt annotations, systematic large-scale
transcriptomics and proteomics studies, and co-occurrence
text mining. For use in STITCH, the text-mining evidence
was recomputed based on the same texts used elsewhere in
STITCH. Second, STITCH incorporates baseline expres-
sion patterns from tissues deposited in the Expression At-
las (34). Before augmenting the network with tissues data,
users have to choose if they want to use data fromTISSUES
or Expression Atlas. The TISSUES resource contains con-
fidence levels ranging from one (lowest confidence) to five
(highest confidence). Accordingly, on the STITCH website
users can select a tissue and a minimum confidence level.
In contrast, datasets from the Expression Atlas are trans-
formed into percentiles. The confidence score for a protein–
protein interaction in the given tissue is thenmultiplied with
the geometric mean of the two proteins’ expression per-
centiles. For protein–chemical interactions, the confidence
score is multiplied with the protein’s expression percentile.
To access the tissue expression patterns, users can search for
tissues either by typing parts of the tissue names or by select-
ing a tissue from a list. Then, users can submit the changed
settings to STITCH. In return, an updated network will be
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Figure 1. Display of binding affinities. The user interface of STITCH has been updated and the option to scale edge width of protein–chemical interactions
according to binding affinity has been added. The shown network of multiple NSAIDs makes their different binding affinities clear: for example, aspirin
has relatively low binding affinities, whereas rofecoxib is specifically binding PTGS2.
shown. As non-expressed nodes are removed (using TIS-
SUES) or confidence values get updated (using Expression
Atlas), other interaction partners may become part of the
network.
USE CASES
STITCH has been widely used for a variety of different
purposes. These fall into three broad classes: (i) small- to
medium-scale analyses performed via the web interface, (ii)
large-scale analyses thatmake use of the bulk download files
and (iii) reuse of data fromSTITCH for development of new
web-based resources.
Work by O’Reilly et al. on identifying potential drug
targets for 1-antitrypsin deficiency exemplifies the web-
based usage (35). Through a genome-wide RNAi screen in
a Caenorhabditis elegans disease model, the authors identi-
fied 104 C. elegans genes of interest (having 85 human or-
thologs). To validate these as potential drug targets, the au-
thors queried STITCH and MetaCore for each of the hu-
man proteins and thereby identified a compounds for use
in follow-up experiments. Conversely, STITCH can also be
queried for a set of chemicals to identify possible targets,
as exemplified by the screen by Kumar et al. of compounds
capable of altering intracellular manganese levels (36). The
ability to see binding affinities in the new web interface
makes STITCH 5 even better suited for such use cases than
previous versions.
STITCH is also commonly used for large-scale analy-
ses, which we facilitate by making the data available for
bulk download. Ligeti et al. used these files to construct a
network neighborhood of proteins around each drug and
showed that the neighborhood overlap of two drugs can
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Figure 2. Filtering interaction networks according to tissue expression pat-
terns. (A) The interaction network around diclofenac and PTGS1/2 is
shown without filtering for tissue expression patterns. In this and the fol-
lowing panels, the top five interaction partners with the highest scores are
shown. (B) Using the TISSUES resource, only proteins believed to be ex-
pressed in blood platelets (with medium confidence, i.e. three stars in TIS-
SUES) become part of the interaction network. For these settings, PTGS2
is not expressed and is therefore shown in a lighter color. (C) Expression
patterns according to RNA-seq data from the Human Protein Atlas are
used to focus on genes expressed in smooth muscle. Confidence scores of
interactions are scaled by the geometric mean of the binding partners’ ex-
pression percentiles. Due to the recomputed confidence scores, four inter-
action partners have been replaced by other proteins.
predict synergy of drug combinations (37). On a related
note, Vogt et al. made use of both the drug thesaurus and
the protein–chemical interaction from STITCH to predict
drug contraindications (38).
Last, but not least, the integrated data provided by
STITCH is useful to researchers who develop their ownweb
resources and prediction methods. An example of this is the
ChemDIS resource, which combines the protein–chemical
interactions from STITCH with tools for gene enrichment
analysis to link chemicals via proteins to GO terms, path-
ways and diseases (39). The experimental protein–chemical
interactions from STITCH are also sometimes used as a
benchmark set when developing prediction methods as ex-
emplified by Zhou et al. (40).
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